IPO
IPO filing, visualized

vVARDIS Holding AG

Drill-free treatment for early-stage tooth decay · Zug, Switzerland

VVVV · NYSESwitzerlandF-1 · foreign private issuerSEC cleared Nov 12, 2026

Pinch-zoom for details.

The offering

Price range
$21–$24
per Class A share
Shares offered
8.33M
+1.25M over-allotment option
Raise at $22.50 midpoint
$187.5M
8,333,334 × $22.50, before fees
Net proceeds (company est.)
$166.2M
$192.3M with the option

Use of proceeds, per the filing: general corporate purposes (working capital, operating expenses, capital expenditures), and possibly acquisitions. No dividends planned.

What the company does

vVARDIS sells Curodont, a peptide-based liquid applied to early-stage cavities. The company says it helps stop the decay and rebuild enamel without drilling, in a treatment of up to five minutes.

  • U.S. launch: January 2024. In the U.S. it's sold as an over-the-counter drug because of its fluoride; the filing notes the FDA hasn't ruled on its safety or efficacy.
  • Sold to over 20,000 of about 110,000 U.S. general dental practices, and used on over 3.5 million teeth by June 30, 2026 (company estimates).
  • The company puts its U.S. addressable market at about $29 billion (its own estimate).

Revenue is growing fast

Fiscal year

First half (Jan–Jun)

Growth FY2025
+148.5%
Growth H1 2026
+214.2%
Gross margin H1 2026
86.4%
FY2025: 74.2%

…but it still loses money

Net loss, fiscal year

Net loss, first half

Selling, general & administrative costs were $59.9M in FY2025, about twice revenue. Interest expense was $11.8M. Cash used in operations: $16.3M in H1 2026.

Almost all sales are in the U.S., through a few customers

United States
95.1%
Rest of world
4.9%
Largest customer
72%
2nd customer
13%

Share of FY2025 net revenue ($30.2M). U.S. $28.7M; Switzerland, Italy, U.K. and others $1.5M. The filing doesn't name the customers.

Cash before and after the IPO

June 30, 2026, actual vs. "pro forma as adjusted" for the offering at the $22.50 midpoint, as shown in the filing. Total shareholders' equity goes from −$118.5M to $138.0M on the same basis.

The founders keep control

Co-founders and co-CEOs Haley and Goly Abivardi hold all Class B voting shares. Each Class B share has a tenth of the par value of a Class A share but the same one vote.

Voting power
87.6%
Economic stake
56.4%

Founders' share after the offering, without the over-allotment option. Other holders above 5% economic after the IPO: Curo Bidco 8.8%, Heartland Dental 7.0%, Cerebro Equity 5.1%. The company will be a "controlled company" under NYSE rules.

Things to weigh

  • Customer concentrationOne customer bought 72% of FY2025 sales.
  • Losses and debtNet loss of $56.4M on $30.2M of revenue in FY2025, with $11.8M of interest expense.
  • Founder control87.6% of the votes stay with the founders; Class A buyers get limited say.
  • Regulatory statusSold in the U.S. as an over-the-counter fluoride product; the FDA hasn't determined its safety or efficacy.

The numbers

$000sH1 2026H1 2025H/HFY2025FY2024YoY
Net revenue28,5589,088+214.2%30,20912,157+148.5%
Cost of goods sold(3,885)(4,417)−12.0%(7,792)(8,269)−5.8%
R&D(7,159)(2,002)+257.6%(4,575)(2,641)+73.2%
SG&A(35,064)(26,750)+31.1%(59,925)(32,213)+86.0%
Loss from operations(17,550)(24,081)−27.1%(42,084)(30,966)+35.9%
Interest expense(9,015)(4,061)+122.0%(11,753)(3,942)+198.1%
Net loss(27,807)(32,057)−13.3%(56,447)(34,737)+62.5%
Operating cash flow(16,317)(22,755)−28.3%(16,333)(23,797)−31.4%
First half, $000sH1 2026H1 2025H/H
Net revenue28,5589,088+214.2%
Cost of goods sold(3,885)(4,417)−12.0%
R&D(7,159)(2,002)+257.6%
SG&A(35,064)(26,750)+31.1%
Loss from operations(17,550)(24,081)−27.1%
Interest expense(9,015)(4,061)+122.0%
Net loss(27,807)(32,057)−13.3%
Operating cash flow(16,317)(22,755)−28.3%
Fiscal year, $000sFY2025FY2024YoY
Net revenue30,20912,157+148.5%
Cost of goods sold(7,792)(8,269)−5.8%
R&D(4,575)(2,641)+73.2%
SG&A(59,925)(32,213)+86.0%
Loss from operations(42,084)(30,966)+35.9%
Interest expense(11,753)(3,942)+198.1%
Net loss(56,447)(34,737)+62.5%
Operating cash flow(16,333)(23,797)−31.4%

H/H: first half 2026 vs first half 2025. YoY: fiscal 2025 vs fiscal 2024. Both are the change in the size of each line, worked out from the filed figures; green means better for the company (more revenue, lower costs or losses), red means worse. FY2024 and FY2025 audited; half-years unaudited. Gross margins for FY2024 (32.0%) and H1 2025 (51.4%) in the charts are worked out from these lines.

Risks

  1. Sales depend on dentists and patients knowing about and accepting Curodont.
  2. Relies on distributors, especially Henry Schein, and a few key customers.
  3. Must keep expanding its sales and marketing to grow.
  4. Depends on outside manufacturers and suppliers.
  5. Its market may be smaller than it estimates.
  6. Depends on its senior management and key staff.

In plain English, from the filing's risk factors.

Strategy

  1. Keep building its direct sales, clinical education and marketing teams.
  2. Raise awareness among dentists, patients and insurers.
  3. Use AI cavity-detection tools to find more treatable cavities.
  4. Expand into more countries.
  5. Use its Curodont technology to add new products.

In plain English, from the filing's growth strategies.

Source: every figure is from vVARDIS's Form F-1/A, Amendment No. 2, filed with the SEC on November 12, 2026 (preliminary prospectus). The final price will be in the 424B4 prospectus. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.